Afuco™ Anti-GD2 ADCC Therapeutic Antibody (Dinutuximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (human/Mouse) antibody expressed in CHO binding to human GD2. Dinutuximab is a chimeric monoclonal antibody that induces antibody dependent cell-mediated cytotoxicity. Dinutuximab is intended as maintenance therapy (targeting minimal residual disease) for high risk neuroblastoma, administered after induction therapy, autologous stem cell transplantation and/or radiotherapy.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-731 |
| Pricing | Inquiry |
| Host | Chimeric |
| Target | GD2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | Neut, ELISA, IF, IP, FuncS, FC |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |